Sort publications on year
-
Pharmaco-Economics
Aspects épidémiologiques et économiques de l’insulinothérapie en Fance métropolitaine
DETOURNAY B
Med Mal Metab ; (2):149-152
-
Pharmaco-Economics
Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2
FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL
Bulletin du Cancer ; 94(7):711-720
-
Pharmaco-Economics
Coût de l’obésité en France
EMERY C, DINET J, LAFUMA A, SERMET C, KHOSHNOOD B, FAGNANI F
Presse Med ; 832-840
-
Pharmaco-Economics
Invasive cervical cancer treatment costs in France
ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG
Bull Cancer ; 94(2):219-224
-
Pharmaco-Economics
Coût de la prise en charge des frottis anormaux et des néoplasies intraépithéliales du col de l’utérus en France
BERGERON C, COHET C, BOUEE S, LORANS C, REMY V
BEH ; (1):4-6
-
Pharmaco-Economics
Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma : analysis conducted on the United Kingdom General Practitioner Research Database
LAFUMA A, BERDEAUX G
Curr Med Res Opin ; 23(12):3009-3016
-
Pharmaco-Economics
Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting
DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F
Oncology ; 72:248-254
-
Pharmaco-Economics
A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France
COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF
Joint Bone Spine ; 31
-
Pharmaco-Economics
Nonmedical economic consequences attribuables to visual impairment nation-wide approach in France
LAFUMA A, BREZIN A, FAGNANI F, MIMAUD V, MESBAH M, BERDEAUX G
Eur J Health Econom ; 7(3):158-164
-
Pharmaco-Economics
Evaluation of non-medical costs associated with visual impairment in four European countries – France, Italy, Germany and the UK
LAFUMA A, BREZIN A, LAPATRIELLO S, HIEKE K, HUTCHINSON J, MIMAUD V, BERDEAUX G
Pharmacoeconomics ; 24(2):193-205
-
Pharmaco-Economics
Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries
BOUEE S, LAFUMA A, FAGNANI F, MEUNIER PJ, REGINSTER JY
Rheumatol Int ; 26(12):1063-72
-
Pharmaco-Economics
Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France
TILLEUL P, LAFUMA A, COLIN X, OZIER Y
Clin Appl Thromb Hemost ; 12(4):473-484
-
Pharmaco-Economics
Cervical cancer screening and associated treatment costs in France
BERGERON C, BREUGELMANS JG, BOUEE S, LORANS C, BENARD S, REMY V
Gynécol Obstét Fertil ; 34:1036-1042
-
Pharmaco-Economics
The economic burden of glaucoma and ocular hypertension
ROULAND JF, BERDEAUX G, LAFUMA A
Drugs Aging ; 22(4):315-321
-
Pharmaco-Economics
Dépistage de la rhétinopathie diabétique par des photographies du fond de l’oeil
AUBERT JP, MASSIN P, AUDRAN G, BEN MEHIDI A, BERNIT B, BOUÉE S, BOUHASSIRA M, BOUROVITCH JC, ERGINAY A, ESCHWÈGE E, JAMET M, MARRE M, NOUGAIREDE M, TCHERNY-LESSENOT S
RevPrat - Médecine Générale ; 19(692-693):588-592